 Analysts at Aegis Capital Corp rated Kintara Therapeutics Inc NASDAQ:KTRA a Buy, while maintaining a 7 share target price on the company which develops new solid tumor cancer therapies. The San Diego, California-based clinical stage drug development company closed its fiscal third quarter with cash and equivalents of about 15.7 million. 